 The FDA has signed off Sorrento Therapeutics Incs NASDAQ: SRNE investigational new drug application IND for Abivertinib Fujovee for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer mCRPC. The MAVERICK study will be conducted in a partnership. 